Localization of Xenobiotic Transporters Expressed at the Human Blood-Testis Barrier

Raymond K. Hau, Robert R. Klein, Stephen H. Wright, and Nathan J. Cherrington

College of Pharmacy, Department of Pharmacology & Toxicology, University of Arizona, Tucson AZ, USA (R.K.H., N.J.C.)

College of Medicine, Department of Pathology, University of Arizona, Tucson, AZ, USA (R.R.K.)

College of Medicine, Department of Physiology, University of Arizona, Tucson, AZ, USA (S.H.W.)
Running Title: Transporter Localization at the Blood-Testis Barrier

Corresponding Author:

Nathan J. Cherrington

1295 N Martin Ave, Tucson, AZ, 85721

(520)-626-0219, cherring@pharmacy.arizona.edu

Text Pages: 45

Number of Tables: 1

Number of Figures: 6

Number of Supplemental Files: 1

Number of References: 104

Number of Words in Abstract: 250

Number of Words in Introduction: 748

Number of Words in Discussion: 1935

Abstract

The blood-testis barrier (BTB) is formed by basal tight junctions between adjacent Sertoli cells (SCs) of the seminiferous tubules and acts as a physical barrier to protect developing germ cells in the adluminal compartment from reproductive toxicants. Xenobiotics, including antivirals, male contraceptives, and cancer chemotherapeutics, are known to cross the BTB, although the mechanisms that permit barrier circumvention are generally unknown. This study used immunohistological staining of human testicular tissue to determine the site of expression for xenobiotic transporters that facilitate transport across the BTB. OAT1, OAT2, and OCTN1 primarily localized to the basal membrane of SCs, whereas OCTN2, MRP3, MRP6, and MRP7 localized to SC basal membranes and peritubular myoid cells (PMCs) surrounding the seminiferous tubules. CNT2 localized to Leydig cells (LCs), PMCs, and SC apicolateral membranes. OCT1, OCT2, and OCT3 mostly localized to PMCs and LCs, although there was minor staining in developing germ cells for OCT3. OATP1A2, OATP1B1, OATP1B3, OATP2A1, OATP2B1 and OATP3A1-v2 localized to SC basal membranes with diffuse staining for some transporters. Notably, OATP1C1 and OATP4A1 primarily localized to LCs. Positive staining for MATE1 was only observed throughout the adluminal compartment. Definitive staining for CNT1, OAT3, MATE2, and OATP6A1 was not observed. The location of these transporters is consistent with their involvement in the movement of xenobiotics across the BTB. Altogether, the localization of these transporters provides insight into the mechanisms of drug disposition across the BTB and will be useful in developing tools to overcome the pharmacokinetic and pharmacodynamic difficulties presented by the BTB.
Significance Statement

Although the total mRNA and protein expression of drug transporters in the testes has been explored, the localization of many transporters at the blood-testis barrier (BTB) has not been determined. This study applied immunohistological staining in human testicular tissues to identify the cellular localization of drug transporters in the testes. The observations made in this study have implications for the development of drugs that can effectively use transporters expressed at the basal membranes of Sertoli cells to bypass the BTB.
Introduction

The blood-testis barrier (BTB) safeguards developing germ cells from the effects of reproductive toxicants. The physical component of the BTB involves basal junctional complexes formed between adjacent Sertoli cells (SCs) to establish a nearly impermeable network of membranes in the seminiferous tubule (Pelletier, 2011). The expression of membrane transporters that limit chemical flux across the basal membrane of SCs constitutes the physiological component of the BTB (Mital et al., 2011; Mruk and Cheng, 2015; Mruk et al., 2011). Moreover, the long, thin peritubular myoid cells (PMCs) surrounding the tubules and interstitial Leydig cells (LCs) may also influence drug disposition across the BTB due to their location and transporter expression. Together, this barrier obstructs efficient delivery of some compounds into and across SCs. However, developing germ cells require a steady supply of nutrients to sustain normal reproductive function in the male genital tract (MGT) during spermatogenesis. Consequently, the movement of nutrients, including nucleosides, hormones, sugars, and metabolites that do not readily diffuse across membranes, must involve transporters. Although these transporters play a physiological role at the BTB, exogenous compounds such as pesticides, cancer chemotherapeutics, male contraceptives, and antivirals can also take advantage of these pathways to circumvent the BTB and ultimately exert pharmacological or toxicological effects in the MGT (Cheng et al., 2005a; Grima et al., 2001; Kato et al., 2005, 2006, 2009; Klein et al., 2013; Miller et al., 2020; Miller et al., 2021a; Tash et al., 2008a; Tash et al., 2008b). Although some compounds are known to cross the BTB, studies assessing the
localization and function of the responsible drug transporters have been insufficient for developing a global picture of drug disposition across the BTB.

Some studies have assessed transporter function in SCs; however, fewer have confirmed the presence and location of these transporters in mammalian tissues. Several studies have analyzed the localization of some transporters such as the equilibrative nucleoside transporters (ENTs) and efflux transporters such as multidrug resistance proteins (MRPs), P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) (Bart et al., 2004; Klein et al., 2013; Klein et al., 2014; Koraichi et al., 2013; Melaine et al., 2002; Su et al., 2009). ENT1 was observed to localize to the basal membrane of human and rodent SCs, whereas ENT2 localized to the apicolateral membranes of SCs (Klein et al., 2013). Moreover, functional transport studies confirmed this polarized distribution of ENT1 and ENT2 in primary rat SCs cultured on Transwell inserts (Klein et al., 2013). Consequently, the ENTs act as a mechanism for endogenous nucleosides and nucleoside analog drugs to circumvent the BTB, facilitating uptake at the basal pole (ENT1) and efflux at the apicolateral pole (ENT2). These transporters may be important for the disposition of antivirals to treat infections in the MGT due to Zika viruses, Ebolaviruses, human immunodeficiency viruses, and other sexually transmitted viruses.

In contrast, studies examining the role of efflux transporters such as P-gp, BCRP, and the MRPs have been more common. These efflux transporters are critically important for maintaining normal endogenous chemical concentrations in the MGT by effluxing toxicants and metabolic wastes back into the blood; however, they do not provide effective pathways for nutrients to enter SCs. Nutrients require
unidirectional/bidirectional uptake transporters expressed at the basal membranes of SCs. But these processes will consequently allow some exogenous compounds to bypass the BTB. Unfortunately, fewer studies have surveyed the role of uptake transporters at the BTB which complicates the drug discovery and development process for compounds designed to specifically target diseases or disorders in the testes. As a result, a more comprehensive drug transporter map of the testes must be generated to better understand drug disposition into the MGT and how these processes may be exploited.

The current study is the first broad investigation of the expression and localization of several drug transporters in human testicular tissue. The expression and localization of each transporter was evaluated by immunohistofluorescence and immunohistochemical staining in several human testicular tissue samples from patients of varying ages and ethnicities. The targeted transporters included pharmacologically relevant processes, such as the organic cation transporters (OCTs), organic cation transporters novel (OCTNs), organic anion transporters (OATs), organic anion transporting polypeptides (OATPs), and multidrug and toxin extrusion proteins (MATEs). Many of these transporters were found to be expressed throughout human testicular tissue where they may play important roles in drug disposition to the MGT. Therefore, the localization of the drug transporters observed in this study should facilitate understanding the pharmacokinetics of various classes of compounds across the BTB and into the MGT.
Methods

Reagents

All reagents were purchased from ThermoFisher Scientific (ThermoFisher Scientific, Waltham, MA, USA) unless otherwise noted. Primary and secondary antibodies were purchased from the vendors listed in Table 1 and used at the indicated concentrations. The anti-OATP1A2, OATP1B1, OATP1B3, OATP1C1, OATP3A1_v2, and OATP4A1 antibodies used in this study were a kind gift from Dr. Bruno Stieger of the Department of Clinical Pharmacology and Toxicology at the University of Zurich (Zürich, Switzerland).

Sample Collection

Formalin-fixed, paraffin-embedded human testicular tissue blocks were obtained from eight different patients ranging from age 16 to 65 from the Department of Pathology tissue archive at the Banner-University Medical Center (Tucson, AZ, USA). Each tissue block was examined by a board-certified pathologist (Dr. Robert Klein) that confirmed the tissue was sufficiently healthy and intact for immunohistological experiments. Protocols for obtaining human tissues were approved by the University of Arizona Institutional Review Board under protocol number: 1906692571.
Immunohistofluorescence Staining

Sectioning of all formalin-fixed paraffin-embedded tissue samples was accomplished using a microtome with sections sliced five-micron thick. Tissue slides were deparaffinized by immersion into xylenes three consecutive times for 4 min each. Next, tissues were rehydrated with a graded series of ethanol and water as follows: 3X 100% ethanol for 4 min, 2X 95% ethanol for 4 min, 1X 75% ethanol for 4 min, and 2X 100% water for 4 min. Antigen retrieval was performed by submerging tissue slides in citrate buffer (pH 6.0) or Tris-EGTA buffer (10 mM Tris, 0.5 mM EGTA, pH 9.0) and boiling in a microwave oven for 6 min. After heating the samples, the buffer was replaced with room temperature buffer, placed on ice for 20 min, then rinsed under cold tap water for 10 min.

Non-specific epitopes in each tissue sample were blocked using a solution of 4% fish skin gelatin and 5% goat/donkey serum in PBS containing 0.1% Triton X-100 (PBS-T) for 30 min. Tissue samples were washed once with PBS-T and then probed overnight at 4°C with the primary antibody diluted in 1% fish skin gelatin and 2% goat/donkey serum in PBS-T. The following day, each sample was washed once more with PBS-T. An appropriate Alexa Fluor 488 secondary antibody diluted in 1% fish skin gelatin and 2% goat/donkey serum in PBS-T was applied for 1 hr at room temperature and washed again with PBS-T. Nuclei were counterstained using 1 μg/mL DAPI. Tissue autofluorescence was blocked using TrueBlack® Lipofuscin Autofluorescence Quencher (Biotium, Fremont, CA, USA, Catalog #23007) according to the manufacturer’s protocol. Coverslips were mounted using ProLong™ Diamond Antifade
Mountant (Invitrogen, Carlsbad, CA, USA, Catalog #P36961) and allowed to dry in the dark overnight before imaging. Slides were imaged using a Leica SP5-II confocal microscope (Leica Camera AG, Wetzlar, Germany) with a HC PL APO 40x/1.25 GLYC CORR CS2 objective. Images were further processed by linear histogram stretching for the blue and green color channels independently to clearly visualize positive staining using Adobe Photoshop CC 2019 (Adobe, San Jose, CA, USA). The image representing the green channel for Alexa Fluor 488-stained proteins and the image representing the blue channel for DAPI-stained nuclei were superimposed to generate the final representative, merged image for each figure. Bright-field images were captured for each sample to illustrate tissue structure. Each experiment included two negative control slides in which one slide was not exposed to any primary antibodies but was treated with a secondary antibody and the second was not exposed to any primary or secondary antibodies. The negative control slides were treated the same as the other tissue samples and exhibited no positive or background staining. Images were cropped from the original image to illustrate clearer staining patterns. At least two to three different tissue samples were used to test each antibody in immunohistofluorescence or immunohistochemical experiments, and the images shown are representative of at least two similar observations.

**Immunohistochemical Staining**

Immunohistochemical staining of tissues were performed with similar steps as described in the ‘Immunohistofluorescence Staining’ methods section with some differences. Briefly, five-micron tissue sections were deparaffinized with xylenes and
rehydrated with graded ethanol and water. Antigen retrieval was performed for each tissue sample and endogenous peroxidases were quenched using 3% $\text{H}_2\text{O}_2$ in methanol for 20 min. Tissues were washed once with PBS-T before incubating with Background Sniper (Biocare Medical, Pacheco, CA, USA, Catalog #BS966) for 10 min. Tissues were washed once more PBS-T and probed overnight at 4°C with a primary antibody diluted in 1% fish skin gelatin and 5% BSA in PBS-T. The following day, each sample was washed once more with PBS-T and then probed with MACH 4 Universal HRP-Polymer (Biocare Medical, Pacheco, CA, USA, Catalog #M4U534) for 15 min. Tissue slides were further developed using the Betazoid DAB Chromogen Kit (Biocare Medical, Pacheco, CA, USA, Catalog #BDB2004) and rinsed several times with water. Nuclei were counterstained with Hematoxylin Solution, Gill No. 3 (Sigma-Aldrich, St. Louis, MO, USA, Catalog #GHS332-1L) for 15 sec. Tissues were then dehydrated in graded ethanol and xylenes. Coverslips were mounted with Cytoseal™ Mountant XYL (ThermoFisher Scientific, Waltham, MA, USA, Catalog #22050262) and allowed to dry overnight before imaging. All slides were imaged using a Leica DM3000 microscope (Leica Camera AG, Wetzlar, Germany) with a HC PL APO 40x/0.85 CORR objective. Representative images were further processed by linear histogram stretching to clearly visualize positive staining using Adobe Photoshop CC 2019 (Adobe, San Jose, CA, USA). Each experiment included a negative control slide that was not exposed to any primary antibodies but was treated the same as the other tissue samples. There was no positive staining observed in the negative control slides. Some images were cropped from the original image to illustrate clearer staining patterns.
Results

**Immunohistofluorescent staining of concentrative nucleoside transporters**

The distribution of the concentrative nucleoside transporters in human testicular tissues was evaluated by immunohistofluorescence. Positive staining for concentrative nucleoside transporter 1 (CNT1) was not observed at varying antibody concentrations in different tissue samples (data not shown). Further analysis of CNT1 antibody specificity was performed with liver tissue due to its high expression (Pennycooke et al., 2001). Intense punctate staining for CNT1 was observed throughout the cytosol of hepatocytes (Figure S1E), which is consistent with a previous report on the canalicular and intracellular localization in rat liver tissues (Duflot et al., 2002). This intracellular staining was attributed to a transcytotic process that re-localizes CNT1 from the sinusoidal membrane to intracellular endosomes and the canalicular membrane. No observable staining was observed in liver tissue that was only probed with a secondary antibody or neither antibody (Figures S1A and S1C). Although positive CNT1 staining was absent in the testes, CNT2 was observed to be primarily localized to the apicolateral membranes.
of SCs in the ectoplasmic specialization between germ cells and in vascular endothelial cells with minor staining in PMCs surrounding the tubules and in LCs (Figure 1E).

*Immunohistofluorescent staining of organic cation transporters*

Immunohistofluorescent staining was also performed for the OCTs and OCTNs in human testes. OCT1, OCT2, and OCT3 localized to PMCs and LCs, although there was minor staining in the developing germ cells within the seminiferous tubules for OCT3 (Figures 2A, 2C, and 2E). Interestingly, moderate staining of OCT1 and OCT2 was also detected along the basal membrane of SCs, whereas staining for OCT3 at this location was less pronounced. Similarly, positive staining for OCTN2 was observed at PMCs and LCs with more distinct staining along the basal membranes of SCs (Figures 2I). On the other hand, OCTN1 only localized to the basal membrane of SCs with a lack of staining throughout the rest of the tissue (Figure 2G). These staining patterns were consistent with their role as uptake transporters in other tissues such as the kidneys, intestines, and lungs.

*Immunohistofluorescent staining of organic anion transporters*

In addition to the OCTs, the expression and localization of the OATs in human testicular tissue was examined. Both OAT1 and OAT2 were primarily localized along the basal membrane of SCs, consistent with their role in compound uptake, with minor staining throughout the adluminal compartment of the seminiferous tubules for OAT2 (Figures 3A and 3C). Some positive staining was also observed for OAT1 in LCs and vascular endothelial cells, although it was primarily expressed by SCs (Figure 3A).
Definitive staining for OAT3 in several human testicular tissue samples was not observed for any antibody concentrations employed (data not shown). Immunocytofluorescence staining for CHO cells overexpressing human OAT3 with a C-terminal Flag epitope tag was performed with the same antibody at a 1:100 dilution and an anti-Flag epitope antibody at a 1:10 dilution. CHO-OAT3 cells probed with the anti-Flag antibody exhibited positive staining along the membranes with minor staining in the cytosol (Figure S2B). The anti-OAT3 antibody produced intense positive staining throughout the cytosol of CHO-OAT3 cells (Figure S2D), indicating greater non-specificity and that OAT3 may still be expressed in the testes. Both control cell lines did not exhibit positive staining when probed with either antibody (Figures S2A and S2C).

**Immunohistochemical staining of organic anion transporting polypeptides**

Standard immunohistochemical staining for the OATPs was performed on human testicular tissue due to unreliable staining with immunohistofluorescent methods. Intense positive staining in brown for OATP1A2, OATP1B1, OATP1B3, OATP2A1, OATP2B1, and OATP3A1-v2 was primarily observed along the basal membrane of SCs; however, diffuse staining throughout the adluminal compartment of the seminiferous tubules was also noted (Figures 4B-D and 4F-H). Positive basal membrane staining of OATP1B3 and OATP2A1 was less intense than other transporters but was distinctly different than in the control tissue (Figures 4A, 4D, and 4F). Diffuse staining in LCs was also noted for OATP1A2, OATP1B1, and OATP1B3 (Figures 4B-D). OATP1C1 and OATP4A1 were predominantly localized to LCs with some diffuse staining throughout the rest of the tissue. (Figures 4E and 4I). Additionally,
the location of OATP1C1 observed in this study is consistent with a previous report of its localization in LCs in human testes (Pizzagalli et al., 2002).

Positive staining for OATP6A1 was not observed with the antibody or tissues tested with immunohistochemical- or -fluorescence-based detection methods (data not shown). Immunocytofluorescence staining for CHO cells overexpressing human OATP6A1 with a C-terminal V5 epitope tag was performed with the same antibody at a 1:100 dilution and an anti-V5 epitope antibody at a 1:1000 dilution. Both antibodies produced an intense positive signal throughout the cytosol of CHO-OATP6A1 cells (Figures S3B and S4D), which is consistent with the lack of functional membrane expression from previous studies (data not shown). These observations indicate antibody specificity for OATP6A1, although its binding epitope may not be appropriate for immunohistology. Control cells probed with either antibody did not produce an observable signal (Figures S3A and S3C).

*Immunohistofluorescent staining of multidrug resistance proteins*

Previous work has determined the localization of several MRPs in rodent, human, and non-human primate testicular tissue. However, definitive staining for MRP3, MRP6, and MRP7 in testicular tissues have not been explored. Consequently, immunohistofluorescence staining for MRP3, MRP6, and MRP7 was performed on human testicular tissues to determine the localization of these proteins. MRP3, MRP6, and MRP7 were primarily localized to the basal membranes of SCs with minor staining at the PMCs (Figures 5A, 5C, 5E) where they may serve as one of many essential efflux transport processes to protect SCs and developing germ cells from metabolites or...
toxicants. In addition to these locations, minor positive staining was observed for each of the three transporters in LCs as well as in vascular endothelial cells for MRP7 only.

**Immunohistofluorescent staining of multidrug and toxin extrusion proteins**

The localization of MATE1 was identified by immunohistofluorescence staining in human testicular tissue. Positive staining for MATE1 was primarily observed throughout the adluminal compartment of the seminiferous tubules with minor staining was observed at the PMCs and LCs (Figure 6A). Conclusive staining for MATE2 was not observed with the antibody or testicular tissues tested (data not shown). Immunocytofluorescence staining for CHO cells overexpressing human MATE2-K with a C-terminal V5 epitope tag was performed with the same antibody at a 1:100 dilution and an anti-V5 epitope antibody at a 1:1000 dilution. Although MATE2-K is a kidney-specific isoform, the anti-MATE2 antibody used in this study recognizes an extracellular C-terminal epitope which is present in the canonical and kidney-specific isoforms. Both antibodies produced a positive signal in the cytosol of CHO-MATE2-K cells with some plasma membrane staining, indicating specific staining for MATE2 (Figures SB and S4D) with no observable staining in control cells (Figures S4A and S4C).
Discussion

Among the various transporters expressed at the BTB, the expression, localization, and function of the ENTs has been rigorously studied (Hau et al., 2020; Kato et al., 2005, 2006, 2009; Klein et al., 2013; Miller et al., 2020; Miller et al., 2021a; Miller et al., 2021b; Miller et al., 2021c). Unfortunately, the physiological and pharmacological roles of the CNTs in the testes has been understudied. A recent study noted the mRNA expression of CNT1 and CNT2 in human SCs (Hau et al., 2020). However, CNT1 was not detected in human testicular tissue, but was evident in human liver tissue (Figure S1E) in the present study. Moreover, the expression and function of this transporter has been observed in rat SCs (Kato et al., 2005, 2009). Here, CNT2 predominantly localized to the apicolateral membranes of SCs in human testes (Figure 1E), but the role for this transporter at this location is unknown. Previous reports identifying the localization of the structural protein, vimentin, in rat testes show that it adopts a similar staining pattern as CNT2 along the apicolateral membranes of SCs (Kopecky et al., 2005). It was recently reported that uptake of uridine in a human SC
line was primarily ENT1-mediated with negligible contribution from ENT2 or the CNTs (Hau et al., 2020). Nevertheless, it is possible that CNT2 delivers nucleosides from the cytoplasm of SCs to the space between SCs and developing germ cells (Gray et al., 2004). Free nucleosides that accumulate in this space can then be taken up by other nucleoside transporters expressed by germ cells. Another possibility is that CNT2 salvages free nucleosides from the adluminal compartment, although further work is required to define the role of CNT2 in the testes. Altogether, CNT2 could play a significant role in the disposition of nucleosides and nucleoside analog antivirals between SCs and the adluminal compartment.

The OCTs are primarily expressed in the liver and kidneys and are involved in the uptake of cationic compounds such as choline, histamine, and metformin from the blood. This is the first study to explore OCT localization in human testicular tissue. Expression of OCT mRNA has been reported in the testes and SCs (Augustine et al., 2005; Hau et al., 2020; Maeda et al., 2007), and here, OCT1, OCT2, and OCT3 localized to PMCs and LCs with minor positive staining at the basal membrane of SCs or throughout the adluminal compartment for OCT3 (Figures 2A, 2C, and 2E). One study assessed the OCTs in cultured rat SCs and noted the lack of expression of OCT2, although OCT1 and OCT3 were shown to be functionally expressed by measuring $[^{14}\text{C}]$-TEA uptake (Maeda et al., 2007). Based on transepithelial transport experiments with rat SCs cultured on Transwell inserts, the authors also concluded OCT1 was expressed on the basal membrane and OCT3 was expressed on the apical membrane of SCs (Maeda et al., 2007), but the present results cannot confirm that in human SCs. It must be noted that cultured SCs do not form a tight, impermeable barrier compared to MDCK
or Caco-2 cells. Typical transepithelial electrical resistance values for SCs cultured on Transwell inserts reach a peak value of ~10-70 Ohms•cm$^2$ depending on species, cell type, and culture conditions, which are a stark contrast to the 1000+ Ohms•cm$^2$ of MDCK and Caco-2 cells (Chui et al., 2011; Gerber et al., 2020; Hau et al., 2020; Mruk and Cheng, 2011; Papadopoulos et al., 2016; Prozialeck and Lamar, 1997; Siemann et al., 2017; Srinivasan et al., 2015; Tsetsarkin et al., 2020; Wu et al., 2019). Consequently, the barrier physiology of these SCs in culture are not completely representative of the in vivo BTB and conclusions that rely on protein localization of the OCTs in culture models are controversial.

In addition to the OCTs, OCTN1 and OCTN2 were observed to localize to the basal membrane of SCs, although OCTN2 also localized to PMCs (Figures 2G and 2I). OCTN1 and OCTN2 are known to transport L-carnitine, which is important in maintaining normal male reproductive function, although ergothioneine is the preferred substrate for OCTN1 (Agarwal and Said, 2004; Grundemann et al., 2005; Kobayashi et al., 2005; Palmero et al., 2000; Tamai et al., 1997; Wang et al., 1999). Previous studies suggested that OCTN2 localizes to the basal membrane of SCs by assessing [$^3$H]-L-carnitine and [$^{14}$C]-TEA uptake across rat SC monolayers cultured on Transwell inserts, where rat OCTN1 is a low affinity transporter for TEA and rat OCTN2 has a significantly higher affinity (Kobayashi et al., 2005; Maeda et al., 2007). The functional data for OCTN2 illustrated in those studies is consistent with the immunohistological observations made here. However, one of the aforementioned studies also speculated that OCTN1 localizes to the apicolateral membrane of rat SCs (Maeda et al., 2007), which is contrary to the basal membrane localization in the present study. These
conclusions were also made based on transepithelial transport studies that demonstrated 200 μM and 20 mM unlabeled TEA inhibited basal to apicolateral flux of [\(^{14}\)C]-TEA, whereas only 20 mM unlabeled TEA inhibited apicolateral to basal flux. Due to these differences in TEA flux through each membrane, the authors concluded that the low affinity TEA transporter, OCTN1, was localized to the apicolateral membrane of SCs. However, this study did not directly assess the function or localization of OCTN1 in cultured cells or tissue. As a result, additional studies that evaluate the expression, localization, and function of the OCTNs are required to provide a comprehensive understanding of disposition across the BTB.

The expression of some OATs and OATPs has been observed in SCs, although there is a lack of information regarding their localization and function in drug disposition in the testes (Augustine et al., 2005; Bleasby et al., 2006; Cheng et al., 2005b; Hau et al., 2020; Huber et al., 2007; Kullak-Ublick et al., 1995; Schnabolk et al., 2010; Suzuki et al., 2003). These transporters are typically studied in the context of drug disposition to the kidneys or liver; however, they may play a major role in the delivery of some compounds across the BTB. The OATs and OATPs transport many endogenous molecules, including prostaglandins, thyroid hormones, and steroids as well as drugs (e.g., statins, antivirals, and NSAIDS) with varying specificity and selectivity. SCs require these endogenous chemicals to maintain normal spermatogenic processes, which suggests that OATs and OATPs may be involved (Frungieri et al., 2015; Rey-Ares et al., 2018; Wagner et al., 2008; Walker and Cheng, 2005). The basal membrane localization of OAT1, OAT2, OATP1A2, OATP1B1, OATP1B3, OATP2A1, OATP2B1, and OATP3A1-v2 (Figures 3A-B, 4B-D, and 4F-H) may play a role in the uptake of
these compounds into SCs, although bidirectional transport is possible for the OATPs. Furthermore, the diffuse staining observed in the adluminal compartment for OATP1A2, OATP1B1, OATP1B3, OATP2B1, and OATP3A1-v2 introduce an interesting mechanism for bidirectional transport across the apicolateral membranes of SCs to supply nutrients for developing germ cells or to recycle compounds in the lumen (Figures 4B-D and 4G-H). Expression of transporters at basal and apical membranes is not a novel discovery as it has been observed for some transporters such as OATP1A2 or P-gp in the brain (Ashraf et al., 2014; Gao et al., 1999; Ose et al., 2010; Sano et al., 2018); however, expression at one membrane may be higher than the other. It is also possible that the custom OATP antibodies (provided by Dr. Bruno Stieger) used in this study also targeted non-specific epitopes in human testicular tissues, although there is a large body of evidence supporting their specificity (Gao et al., 2000; Gao et al., 2005; Huber et al., 2007; Kullak-Ublick et al., 2001; Patik et al., 2015; Patik et al., 2018; Pizzagalli et al., 2002; St-Pierre et al., 2002; Zhang et al., 2017; Zhang et al., 2020). Nevertheless, further studies will have to assess the functional expression of these transporters at the basal and/or apicolateral membranes of SCs.

OATP2A1 localization to the basal membrane of SCs is consistent with its role as the prototypical prostaglandin transporter because SCs produce prostaglandins and respond to extracellular prostaglandins, which would be permitted entry or efflux into SCs via OATP2A1 (Cooper and Carpenter, 1987; Samy et al., 2000; Wilhelm et al., 2005). Additionally, diffuse staining of OATP3A1-v2 in seminiferous tubules with the same antibody has been shown in another study, although basal membrane staining was less evident (Huber et al., 2007). Intense staining for OATP1C1 was observed in
LCs (Figure 4E), which is consistent with its primary role as a thyroid hormone transporter and a previous report showing its localization in LCs in human testicular tissue (Pizzagalli et al., 2002). OATP4A1 was also observed in LCs (Figure 4I) where it may also function as a thyroid hormone transporter (Fujiwara et al., 2001). However, additional studies are required to verify the physiological function of these transporters in the testes.

Although OATP6A1 is a known testes-specific transporter (Fietz et al., 2013; Suzuki et al., 2003), the antibody tested in this study did not exhibit positive staining in several testicular tissue samples. However, OATP6A1 expression was observed in a heterologous expressing CHO cell line using the same antibody, suggesting the experimental applicability of this antibody in these tissues may not be entirely appropriate due to issues with specimen handling during collection or tissue fixation. OATP6A1 function has been poorly characterized; however, its upregulated expression in certain cancers implies an important physiological role (Lee et al., 2004). Altogether, the distribution of unidirectional/bidirectional uptake transporters observed here unveils potential mechanisms to effectively deliver pharmaceutics across the BTB and into the MGT but will require functional transport experiments with appropriate models before proceeding with targeted studies.

Several efflux transporters such as P-gp, BCRP, and some MRPs have been shown to be expressed at the basal or apicolateral membranes of SCs (Bart et al., 2004; Klein et al., 2014; Koraichi et al., 2013; Melaine et al., 2002; Su et al., 2009). However, the localization of MRP3, MRP6, and MRP7 to the basal membrane of SCs and the PMCs are the first to be identified here (Figures 5A, 5C, 5E). The MRPs that
localize to PMCs may act as a first-line defense mechanism to prevent toxicants from reaching the SCs, although SCs can also efflux the toxicants that get through PMCs. Interestingly, MATE1 localized throughout the adluminal compartment of SCs, where apicolateral membrane expression would permit efflux into the lumen may be coupled with OCT and OCTN uptake at the basal membranes of SCs (Figure 6A). Cytosolic staining for MATE1 in SCs is likely attributed to expression along the membranes of intracellular vesicles involved in the endosomal-lysosomal pathway as observed in a previous study (Martinez-Guerrero et al., 2016). In the same study, MATE1 was shown to sequester organic cations in these intracellular vesicles (Martinez-Guerrero et al., 2016), which may serve a physiologically important role in SCs for storing OCT/OCTN substrates in reservoirs to maintain normal spermatogenic processes. However, the physiological and pharmacological roles of these efflux transporters in the testes compared to well-studied efflux transporters such as P-gp, BCRP, MRP1 and MRP2 has been understudied. Consequently, these transporters may adversely influence the disposition of drugs to the MGT to achieve their intended therapeutic effect and these observations must be taken into consideration.

In conclusion, this study is the first to broadly identify the localization of several pharmacologically relevant drug transporters at the BTB. These data will require additional validation in appropriate in vitro and in vivo models to further understand drug disposition in the testes. However, these findings provide insight into the mechanisms by which chemical contraceptives, antivirals, cancer chemotherapeutics, environmental toxicants, and other relevant compounds can circumvent the BTB to provide therapy to MGT-related disorders.
Acknowledgements

The authors thank Dr. Bruno Stieger of the Department of Clinical Pharmacology and Toxicology at the University of Zurich (Zürich, Switzerland) for providing several anti-OATP antibodies for this study. Additionally, the authors thank Doug Cromey of the Department of SWEHSC Cellular Imaging Facility Core at the University of Arizona (Tucson, AZ, USA) for his advice regarding microscopy and imaging. The authors also thank Dr. John Kanady of the Department of Physiology at the University of Arizona (Tucson, AZ, USA) for his advice on immunohistology and fluorescence microscopy.

Authorship Contributions

*Participated in research design: Hau, Klein, Wright, and Cherrington*
Conducted experiments: Hau

Performed data analysis: Hau, Klein, Wright, and Cherrington

Wrote or contributed to the writing of the manuscript: Hau, Klein, Wright, and Cherrington

References


Mital, P., Hinton, B.T., and Dufour, J.M. (2011). The blood-testis and blood-epididymis barriers are more than just their tight junctions. Biol Reprod 84, 851-858.


agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cells. Biol Reprod 78, 1139-1152.


Zhang, Y., Ruggiero, M., and Hagenbuch, B. (2020). OATP1B3 Expression and Function is Modulated by Coexpression with OCT1, OATP1B1, and NTCP. Drug Metab Dispos 48, 622-630.

Footnotes

This work was supported by funding from the National Institutes of General Medical Sciences [Grants GM123643 and GM129777], National Institute of Environmental Health Sciences [Grant ES028668 and ES007091], and National Cancer Institute [Grant CA023074]. The authors declare no conflicts of interest.

Citation of Meeting Abstracts


Reprint Requests
Nathan J. Cherrington, Department of Pharmacology & Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721. Email: cherring@pharmacy.arizona.edu

Figure Legends

**Figure 1:** Immunohistofluorescence analysis for CNT2 in formalin-fixed paraffin-embedded human testicular tissue. Representative control images for all the following immunohistofluorescence experiments that were negative for a fluorescent signal when probed with (A) no primary or secondary antibodies or (C) only a secondary antibody. (E) Positive staining in green for CNT2 primarily observed at the apicolateral membranes of SCs and vascular endothelial cells with minor staining in LCs, PMCs, and germ cells. Nuclei of all cells were counterstained with DAPI in blue. (B, D, F) Bright-field images of each tissue sample illustrates intact tissue structure. Images were captured at 40× magnification with a laser confocal microscope. L indicates the lumen of the seminiferous tubules and v indicates the vascular endothelial cells.

**Figure 2:** Immunohistofluorescence analysis for OCTs and OCTNs in formalin-fixed paraffin-embedded human testicular tissue. (A) OCT1, (C) OCT2, and (E) OCT3 were predominantly localized to PMCs and LCs with minor staining around developing germ cells for OCT3. Distinct staining along the basal membranes of SCs for (G) OCTN1 and (I) OCTN2 was observed. Additional staining for (I) OCTN2 was also
noted at PMCs and LCs. Nuclei of all cells were counterstained with DAPI in blue. (B, D, F, H, J) Bright-field images of each tissue sample illustrates intact tissue structure. Images were captured at 40× magnification with a laser confocal microscope. L indicates the lumen of the seminiferous tubules.

**Figure 3: Immunohistofluorescence analysis for OATs in formalin-fixed paraffin-embedded human testicular tissue.** Intense positive staining in green for (A) OAT1 and (C) OAT2 along the basal membranes of SCs with minor staining in the adluminal compartment for OAT2. Some staining for OAT1 was also detected in LCs and vascular endothelial cells with no additional noteworthy staining for OAT2. Nuclei of all cells were counterstained with DAPI in blue. (B, D) Bright-field images of each tissue sample illustrates intact tissue structure. Images were captured at 40× magnification with a laser confocal microscope. L indicates the lumen of the seminiferous tubules and v indicates the vascular endothelial cells.

**Figure 4: Immunohistochemical analysis for OATPs in formalin-fixed paraffin-embedded human testicular tissue.** (A) Representative control image for the following immunohistochemical experiments that indicated a lack of positive staining when tissues were not exposed to a primary antibody. Positive staining in brown was observed for (B) OATP1A2, (C) OATP1B1, (D) OATP1B3, (F) OATP2A1, (G) OATP2B1 and (H) OATP3A1-v2 along the basal membranes of SCs with diffuse staining within the tubules. Diffuse staining for (A) OATP1A2, (B) OATP1B1, and (C) OATP1B3 was also noted in LCs. (E) OATP1C1 and (I) OATP4A1 were primarily detected in LCs. Nuclei of
all cells were counterstained with hematoxylin. Images were captured at 40× magnification with a standard light microscope. L indicates the lumen of the seminiferous tubules.

Figure 5: Immunohistofluorescence analysis for MRPs in formalin-fixed paraffin-embedded human testicular tissue. (A) MRP3, (C) MRP6, and (E) MRP7 localized to PMCs, LCs, along the basal membrane of SCs, moderately in the adluminal compartment of the seminiferous tubules, and in vascular endothelial cells for MRP7. Nuclei of all cells were counterstained with DAPI in blue. (B, D, F) Bright-field images of each tissue sample illustrates intact tissue structure. Images were captured at 40× magnification with a laser confocal microscope. L indicates the lumen of the seminiferous tubules and v indicates the vascular endothelial cells.

Figure 6: Immunohistofluorescence analysis for MATE1 in formalin-fixed paraffin-embedded human testicular tissue. (A) Immunohistofluorescent detection of MATE1 in human testicular tissues revealed intense positive staining throughout the adluminal compartment of seminiferous tubules. Minor staining was also noted at PMCs and LCs. Nuclei of all cells were counterstained with DAPI in blue. (B) Bright-field image of the tissue sample illustrates intact tissue structure. Images were captured at 40× magnification with a laser confocal microscope. L indicates the lumen of the seminiferous tubules.
### Tables

**Table 1:** List of primary antibodies used in this study at the indicated concentrations and references assessing their selectivity.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Concentration</th>
<th>Provider</th>
<th>Catalog Number</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>OAT1</td>
<td>1:300</td>
<td>Abcam</td>
<td>ab135924</td>
<td>(Basit et al., 2019)</td>
</tr>
<tr>
<td>OAT2</td>
<td>1:100</td>
<td>Abcam</td>
<td>ab58683</td>
<td>(Lundquist et al., 2014)</td>
</tr>
<tr>
<td>OAT3(^a)</td>
<td>Varied</td>
<td>Biorbyt</td>
<td>orb11178</td>
<td>(Ohara et al., 2015)</td>
</tr>
<tr>
<td>OCT1</td>
<td>1:400</td>
<td>Sigma-Aldrich</td>
<td>AV41516</td>
<td>(Han et al., 2013; Segal et al., 2011; Shao et al., 2014)</td>
</tr>
<tr>
<td>OCT2</td>
<td>1:400</td>
<td>Sigma-Aldrich/Atlas Antibodies</td>
<td>HPA008567</td>
<td>(Chen et al., 2019; Chen et al., 2020; Hubeny et al., 2016; Shao et al., 2014)</td>
</tr>
<tr>
<td>OCT3</td>
<td>1:400</td>
<td>Abcam</td>
<td>ab124826</td>
<td>(Cervenkova et al., 2019; Gai et al., 2016; Le Roy et al., 2016; Patel et al., 2013)</td>
</tr>
<tr>
<td>OCTN1</td>
<td>1:300</td>
<td>Abcam</td>
<td>ab107727</td>
<td>(Dolberg and Reichl, 2018)</td>
</tr>
<tr>
<td>OCTN2</td>
<td>1:400</td>
<td>Abcam</td>
<td>ab180757</td>
<td>(Sekhar et al., 2019)</td>
</tr>
<tr>
<td>OATP1A2</td>
<td>1:500</td>
<td>Bruno Stieger</td>
<td>N/A</td>
<td>(Huber et al., 2007)</td>
</tr>
<tr>
<td>OATP1B1</td>
<td>1:500</td>
<td>Bruno Stieger</td>
<td>N/A</td>
<td>(Huber et al., 2007)</td>
</tr>
<tr>
<td>OATP1B3</td>
<td>1:500</td>
<td>Bruno Stieger</td>
<td>N/A</td>
<td>(Huber et al., 2007)</td>
</tr>
<tr>
<td>OATP1C1</td>
<td>1:500</td>
<td>Bruno Stieger</td>
<td>N/A</td>
<td>(Huber et al., 2007)</td>
</tr>
<tr>
<td>OATP2A1</td>
<td>1:1000</td>
<td>Sigma-Aldrich/Atlas Antibodies</td>
<td>HPA013742</td>
<td>(Jimbo et al., 2020; Patik et al., 2015; Umeno et al., 2015)</td>
</tr>
<tr>
<td>OATP2B1</td>
<td>1:500</td>
<td>Bruno Stieger</td>
<td>N/A</td>
<td>(Huber et al., 2007)</td>
</tr>
<tr>
<td>OATP3A1(^a)</td>
<td>1:250</td>
<td>Bruno Stieger</td>
<td>N/A</td>
<td>(Huber et al., 2007)</td>
</tr>
<tr>
<td>OATP4A1</td>
<td>1:500</td>
<td>Bruno Stieger</td>
<td>N/A</td>
<td>(Huber et al., 2007)</td>
</tr>
<tr>
<td>OATP6A1(^a)</td>
<td>Varied</td>
<td>Sigma-Aldrich/Atlas Antibodies</td>
<td>HPA054126</td>
<td>(Djureinovic et al., 2014; Patik et al., 2015)</td>
</tr>
<tr>
<td>CNT1(^a)</td>
<td>Varied</td>
<td>Abcam</td>
<td>ab192438</td>
<td>(Gandhi et al., 2019; Yamamura et al., 2021)</td>
</tr>
<tr>
<td>CNT2</td>
<td>1:500</td>
<td>Abcam</td>
<td>ab199631</td>
<td>(Klein et al., 2017)</td>
</tr>
<tr>
<td>MRP3</td>
<td>1:200</td>
<td>Abcam</td>
<td>ab3375</td>
<td>(Canet et al., 2015; Hardwick et al., 2011)</td>
</tr>
<tr>
<td>Antibody</td>
<td>Dilution</td>
<td>Supplier</td>
<td>Catalog Number</td>
<td>Source(s)</td>
</tr>
<tr>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>MRP6</td>
<td>1:600</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-59618</td>
<td>(Le Saux et al., 2011; Pomozi et al., 2017; Xue et al., 2014)</td>
</tr>
<tr>
<td>MRP7</td>
<td>1:200</td>
<td>Invitrogen</td>
<td>PA5-23652</td>
<td>(Zhang et al., 2014)</td>
</tr>
<tr>
<td>MATE1</td>
<td>1:200</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-138983</td>
<td>(Fujita et al., 2019; Zhang et al., 2019)</td>
</tr>
<tr>
<td>MATE2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Varied</td>
<td>Aviva Systems Biology</td>
<td>ARP51904_P050</td>
<td>None</td>
</tr>
<tr>
<td>V5</td>
<td>1:1000</td>
<td>Invitrogen</td>
<td>R960</td>
<td>(Pelis et al., 2006; Zhang and Wright, 2009)</td>
</tr>
<tr>
<td>Flag</td>
<td>1:10</td>
<td>Developmental Studies Hybridoma Bank</td>
<td>12C6c</td>
<td>None</td>
</tr>
</tbody>
</table>

<sup>a</sup> Antibodies were tested at several concentrations in different testicular tissue samples with inconclusive staining.
Figure 6
Localization of Xenobiotic Transporters Expressed at the Human Blood-Testis Barrier

Supplemental Material

Raymond K. Hau, Robert R. Klein, Stephen H. Wright, and Nathan J. Cherrington
Supplementary Methods

CHO Cell Cultures

Untransfected Flp-In CHO cells were grown in F12K (Sigma-Aldrich, St. Louis, MO, USA, Catalog #N3520) supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 100 μg/mL zeocin in a 37°C humidified 5% CO₂ incubator. CHO cell lines stably expressing a human transporter were grown in the identical medium described above, except with 100 μg/mL hygromycin B instead of zeocin. All cells were washed with standard PBS during routine maintenance.

Immunocytofluorescence Staining

Flp-In CHO, CHO-OAT3, CHO-MATE2-K, and CHO-OATP6A1 cells were grown on round glass coverslips to 80-90% confluence before fixation with 100% ice-cold methanol for 20 min. Non-specific epitopes in each sample were blocked using a solution of 5% goat serum in PBS containing 0.1% Tween 20 (PBS-T) for 30 min. Following epitope blocking, the coverslips were washed with PBS-T three times and the samples were probed with a V5 Tag Monoclonal Antibody (1:1000, Invitrogen, Waltham, MA, USA, Catalog #R960) or a DYKDDDDK (Flag) Tag Antibody (1:10, Developmental Studies Hybridoma Bank, Iowa City, IA, USA, Catalog #12C6c) diluted in PBS-T with 2% goat serum for 1 hr at room temperature. The coverslips were washed three times with PBS-T before probing with Alexa Fluor 488 Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody (1:1000, Invitrogen, Carlsbad, CA, USA, Catalog #A-11001) or Alexa Fluor 488 Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody (1:1000, Invitrogen, Carlsbad, CA, USA, Catalog #A-11008) in PBS-T with 2% goat serum for 1 hr.
at room temperature. Coverslips were washed three times with PBS-T, then rinsed with water before counterstaining the nuclei using 1.5 μg/mL DAPI for 5 min. Following nuclei staining, the coverslips were washed three times with PBS and rinsed once with water before mounting onto glass slides using ProLong™ Diamond Antifade Mountant (Invitrogen, Carlsbad, CA, Catalog #P36970).

Slides were imaged using a Leica SP5-II confocal microscope (Leica Camera AG, Wetzlar, Germany) with a HC PL APO 40x/1.25 GLYC CORR CS2 objective (Leica Camera AG, Wetzlar, Germany). The image representing the green channel for Alexa Fluor 488-stained proteins and the image representing the blue channel for DAPI-stained nuclei were superimposed to generate the final merged image for each figure. The Flp-In CHO cells did not exhibit a fluorescent signal when probed with the V5, Flag, or transporter antibodies. Images were cropped from the original image to illustrate clearer staining patterns.
Supplementary Figures

Supplementary Figure 1: Immunohistofluorescence analysis for CNT1 in formalin-fixed paraffin-embedded human liver tissue. Representative control images for all the following immunohistofluorescence experiments that were negative for a fluorescent signal when probed with (A) no primary or secondary antibodies or (C) only a secondary antibody. (E) Intense punctate staining in green for CNT1 was primarily observed in the cytosol of hepatocytes. Nuclei of all cells were counterstained with DAPI in blue. (B, D, F) Bright-field images of each tissue sample illustrates intact tissue structure. Images were captured at 40× magnification with a laser confocal microscope.
Supplementary Figure 2: Immunocytofluorescence analysis for Flag-tagged human OAT3 in CHO cells. Flp-In CHO or CHO-OAT3 cells were probed with an (A, B) anti-Flag or (C, D) anti-OAT3 antibody to validate antibody specificity. Intense positive staining for (B) V5 was observed at the plasma membrane whereas (D) OAT3 was observed throughout the cytosol of the CHO-OAT3 cell line but no staining was observed in (A, C) Flp-In CHO control cells, indicating greater non-specificity of the OAT3 antibody for membrane-bound proteins. Nuclei of all cells were counterstained with DAPI in blue. Images were captured at 40× magnification with a laser confocal microscope.
**Supplementary Figure 3: Immunocytofluorescence analysis for V5-tagged human OATP6A1 in CHO cells.** Flp-In CHO or CHO-OATP6A1 cells were probed with an (A, B) anti-V5 or (C, D) anti-OATP6A1 antibody to validate antibody specificity. Intense positive staining for V5 and OATP6A1 was observed throughout the cytosol of the (B, D) CHO-OATP6A1 cell line but not in the (A, C) Flp-In CHO control cells, indicating antibody specificity for OATP6A1. Nuclei of all cells were counterstained with DAPI in blue. Images were captured at 40× magnification with a laser confocal microscope.
Supplementary Figure 4: Immunocytofluorescence analysis for V5-tagged human MATE2-K in CHO cells. Flp-In CHO or CHO-MATE2-K cells were probed with an (A, B) anti-V5 or (C, D) anti-MATE2 antibody to validate antibody specificity. Intense positive staining for V5 and MATE2 was observed throughout the cytosol of the (B, D) CHO-MATE2-K cell line but not in the (A, C) Flp-In CHO control cells, indicating antibody specificity for MATE2. Nuclei of all cells were counterstained with DAPI in blue. Images were captured at 40× magnification with a laser confocal microscope.